Halia Therapeutics, Inc.
7 clinical trials · Sponsor
◉ Watch Halia Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Transfusions (NCT07738510) | Halia Therapeutics, Inc. | 2026-10-01 |
| Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers (NCT07399171) | Halia Therapeutics, Inc. | 2026-05-12 |
| A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM (NCT07172867) | Halia Therapeutics, Inc. | 2026-01-06 |
| Study to Evaluate HT-4253 in Healthy Subjects (NCT06537817) | Halia Therapeutics, Inc. | 2024-09-17 |
| Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction (NCT06241742) | Halia Therapeutics, Inc. | 2024-02-12 |
| A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia (NCT07052006) | Halia Therapeutics, Inc. | 2023-12-09 |
| Study to Evaluate HT-6184 in Healthy Subjects (NCT05447546) | Halia Therapeutics, Inc. | 2022-06-15 |
Track Halia Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.